Boston Scientific Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$BSX
Medical/Dental Instruments
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
_____________________________________________________________________
Date of Report (Date of earliest event reported): May 1, 2025
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||||||||
(Address of principal executive offices) (Zip Code)
(508 ) 683-4000
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
(a)Boston Scientific Corporation (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual
Meeting”) on May 1, 2025, in a virtual format via live webcast.
(b) The final voting results for each matter submitted to stockholders at the Annual Meeting are set forth below.
(1) All 10 director nominees were elected to the Company’s Board of Directors for a one-year term, to serve until
the Company’s 2026 Annual Meeting of Stockholders and until their successors have been elected and qualified.
| Nominee | For | Against | Abstain | Broker Non-Votes | ||||||||||||||||||||||
| Yoshiaki Fujimori | 1,233,215,744 | 8,341,968 | 709,321 | 78,045,802 | ||||||||||||||||||||||
| David C. Habiger | 1,183,209,654 | 58,518,407 | 538,972 | 78,045,802 | ||||||||||||||||||||||
| Edward J. Ludwig | 1,201,086,597 | 40,672,845 | 507,591 | 78,045,802 | ||||||||||||||||||||||
| Michael F. Mahoney | 1,147,056,358 | 89,216,861 | 5,993,814 | 78,045,802 | ||||||||||||||||||||||
| Jessica L. Mega | 1,235,908,505 | 5,888,485 | 470,043 | 78,045,802 | ||||||||||||||||||||||
| Susan E. Morano | 1,238,707,400 | 2,478,989 | 1,080,644 | 78,045,802 | ||||||||||||||||||||||
| Cheryl Pegus | 1,239,774,134 | 2,022,767 | 470,132 | 78,045,802 | ||||||||||||||||||||||
| John E. Sununu | 1,169,542,847 | 71,738,782 | 985,404 | 78,045,802 | ||||||||||||||||||||||
| David S. Wichmann | 1,230,866,433 | 10,846,006 | 554,594 | 78,045,802 | ||||||||||||||||||||||
| Ellen M. Zane | 1,203,922,149 | 37,260,931 | 1,083,953 | 78,045,802 | ||||||||||||||||||||||
(2) The stockholders approved, on an advisory basis, the compensation of the Company’s “Named Executive
Officers” as disclosed in the Company’s proxy statement for the Annual Meeting.
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 1,139,414,439 | 100,849,233 | 2,003,361 | 78,045,802 | |||||||||||||||||
(3) The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered
public accounting firm for the 2025 fiscal year.
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 1,206,517,518 | 113,291,050 | 504,267 | 0 | |||||||||||||||||
(4) The stockholders approved, on an advisory basis, the stockholder proposal titled “Support Simple Majority
Vote.”
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 1,178,199,022 | 50,153,851 | 13,914,160 | 78,045,802 | |||||||||||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: | May 6, 2025 | BOSTON SCIENTIFIC CORPORATION | |||||||||
| By: | /s/ Susan Thompson | ||||||||||
| Susan Thompson | |||||||||||
| Vice President, Chief Corporate Counsel and Assistant Secretary | |||||||||||